平台试验设计及案例分析

doi:10.3969/j.issn.1673-5765.2023.06.013

中国卒中杂志 ›› 2023, Vol. 18 ›› Issue (06): 724-730.DOI: 10.3969/j.issn.1673-5765.2023.06.013

• 新型临床试验设计与解读 • 上一篇

平台试验设计及案例分析

王晓宇，张润华，赵博特，刘改芬

1 北京 100070首都医科大学附属北京天坛医院神经病学中心
2 首都医科大学附属北京天坛医院北京市脑血管病防治办公室
3 国家神经系统疾病临床医学研究中心

收稿日期:2023-04-23 出版日期:2023-06-20 发布日期:2023-06-20
通讯作者: 刘改芬 liugaifen1997@163.com
基金资助:
首都医学发展科研基金（2020-1-2041，2022-2G-2049）

Platform Trails and Case Analyses

Received:2023-04-23 Online:2023-06-20 Published:2023-06-20

摘要/Abstract

摘要： 主方案试验设计作为一种新型试验设计方法，已被临床研究广泛应用。平台试验设计是主方案试验设计的重要组成部分，用于长期、动态地评价某种疾病的多种治疗方案。因其具有灵活、共享的特点，被越来越多的学者所认可和采用。本文将从背景、设计思路、重要问题、案例分析等方面对平台试验设计方法进行简要介绍。

关键词: 平台试验设计; 案例分析; 研究设计

Abstract: As a new experimental design method, the master protocol has been widely used in clinical research. The platform trial is an important part of the master protocol design, which is used to evaluate multiple treatment regimens for a single disease in a long-term and dynamic manner, and has been recognized and adopted by a growing number of scholars because of its flexibility and sharing. This paper will briefly introduce the method of platform trail from the aspects of background, design concepts, important issues, and case analyses.

Key words: Platform trail; Case analyses; Study design

王晓宇, 张润华, 赵博特, 刘改芬. 平台试验设计及案例分析[J]. 中国卒中杂志, 2023, 18(06): 724-730.

WANG Xiaoyu, ZHANG Runhua, ZHAO Bote, LIU Gaifen. Platform Trails and Case Analyses [J]. Chinese Journal of Stroke, 2023, 18(06): 724-730.

参考文献

[1] LLEWELLYN-BENNETT R，EDWARDS D，ROBERTS N，et al. Post-trial follow-up methodology in large randomised controlled trials：a systematic review[J]. Trials，2018，19（1）：298.
[2] TANG R，SHEN J，YUAN Y. ComPAS：a bayesian drug combination platform trial design with adaptive shrinkage[J]. Stat Med，2019，38（7）：1120-1134.
[3] MEYER E L，MESENBRINK P，DUNGER-BALDAUF C，et al. The evolution of master protocol clinical trial designs：a systematic literature review[J]. Clin Ther，2020，42（7）：1330-1360.
[4] WOODCOCK J，LAVANGE L M. Master protocols to study multiple therapies，multiple diseases，or both[J]. N Engl J Med，2017，377（1）：62-70.
[5] Food and Drug Administration. Master protocols：efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry[EB/OL].（2018-09-28）[2023-04-16]. https://www.fda.gov/media/120721/download.
[6] BOGIN V. Master protocols：new directions in drug discovery[J/OL]. Contemp Clin Trials Commun，2020，18：100568[2023-04-16]. https://doi.org/10.1016/j.conctc.2020.100568.
[7] 国家药品监督管理局. 药物临床试验适应性设计指导原则（试行）[EB/OL].（2011-12-02）[2023-04-16]. https://www.cde.org.cn/main/news/viewInfoCommon/bc2b326bd49bac7437368272be6ec00d.
[8] PARK J J H，HARARI O，DRON L，et al. An overview of platform trials with a checklist for clinical readers[J/OL]. J Clin Epidemiol，2020，125：1-8[2023-04-16]. https://doi.org/10.1016/j.jclinepi.2020.04.025.
[9] 张怡君，田雪，胥芹，等. 篮式研究和伞式研究及案例分析[J]. 中国卒中杂志，2023，18（2）：240-243.
[10] JAMES N D，SYDES M R，CLARKE N W，et al. Addition of docetaxel，zoledronic acid，or both to first-line long-term hormone therapy in prostate cancer（STAMPEDE）：survival results from an adaptive，multiarm，multistage，platform randomised controlled trial[J]. Lancet，2016，387（10024）：1163-1177.
[11] SYDES M R，PARMAR M K，MASON M D，et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE：a multi-arm multi-stage randomized controlled trial[J/OL]. Trials，2012，13：168[2023-04-16]. https://doi.org/10.1186/1745-6215-13-168.
[12] BARKER A D，SIGMAN C C，KELLOFF G J，et al. I-SPY 2：an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy[J]. Clin Pharmacol Ther，2009，86（1）：97-100.
[13] SYDES M R，PARMAR M K，JAMES N D，et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer：the MRC STAMPEDE trial[J/OL]. Trials，2009，10：39[2023-04-16]. https://doi.org/10.1186/1745-6215-10-39.
[14] SCHIAVONE F，BATHIA R，LETCHEMANAN K，et al. This is a platform alteration：a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols[J]. Trials，2019，20（1）：264.
[15] HAGUE D，TOWNSEND S，MASTERS L，et al. Changing platforms without stopping the train：experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons[J]. Trials，2019，20（1）：294.
[16] THORLUND K，HAGGSTROM J，PARK J J，et al. Key design considerations for adaptive clinical trials：a primer for clinicians[J/OL]. BMJ，2018，360：k698[2023-04-16]. https://doi.org/10.1136/bmj.k698.
[17] PARK J J，THORLUND K，MILLS E J. Critical concepts in adaptive clinical trials[J/OL]. Clin Epidemiol，2018，10：343-351[2023-04-16].
https://doi.org/10.2147/clep.s156708.
[18] PRENTICE R L. Surrogate endpoints in clinical trials：definition and operational criteria[J]. Stat Med，1989，8（4）：431-440.
[19] BEAUCHEMIN C，JOHNSTON J B，LAPIERRE M，et al. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia：a literature-based analysis[J/OL]. Curr Oncol，2015，22（3）：e148-156[2023-04-10]. https://doi.org/10.3747/co.22.2119.
[20] TANEJA S S. Re：addition of docetaxel，zoledronic acid，or both to first-line long-term hormone therapy in prostate cancer（STAMPEDE）：survival results from an adaptive，multiarm，multistage，platform randomised controlled trial[J]. J Urol，2016，196（4）：1124-1125.
[21] STERNBERG C N. Re：addition of docetaxel，zoledronic acid，or both to first-line long-term hormone therapy in prostate cancer（STAMPEDE）：survival results from an adaptive，multiarm，multistage，platform randomised controlled trial[J]. Eur Urol，2016，69（6）：1155-1156.
[22] RECOVERY Collaborative Group. Randomised evaluation of COVID-19 therapy（RECOVERY）[EB/OL].（2020-07-23）[2023-04-16]. https://www.recoverytrial.net/.
[23] HIRAKAWA A，ASANO J，SATO H，et al. Master protocol trials in oncology：review and new trial designs[J/OL]. Contemp Clin Trials Commun，2018，12：1-8[2023-04-16]. https://doi.org/10.1016/j.conctc. 2018.08.009.
[24] 关之玥，刘岩，张晶晶，等. 母方案平台试验设计方法及其在相关领域中的应用[J]. 中国循证医学杂志，2021，21（8）：986-992.

平台试验设计及案例分析

Platform Trails and Case Analyses

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

[1]	金奥铭, 秦宗实, 商洪才, 谷鸿秋. 单病例随机对照试验[J]. 中国卒中杂志, 2023, 18(03): 367-371.
[2]	王孟, 王春娟, 李子孝, 谷鸿秋. 阶梯整群随机试验[J]. 中国卒中杂志, 2023, 18(01): 114-122.
[3]	张艳丽, 金奥铭, 潘岳松. 实效性临床试验：真实世界研究的随机化试验[J]. 中国卒中杂志, 2022, 17(12): 1299-1303.
[4]	金奥铭, 严鸿伊, 向祥龙, 潘岳松. 脑血管病临床研究设计现状、存在的问题及对策[J]. 中国卒中杂志, 2022, 17(01): 21-24.
[5]	潘岳松, 金奥铭, 王梦星. 临床研究样本量的估计方法和常见错误[J]. 中国卒中杂志, 2022, 17(01): 31-35.
[6]	车锋丽，耿晓坤，赵性泉. 情景式案例分析教学法联合标准化病人在神经内科住院医师医患沟通技能教学中的应用[J]. 中国卒中杂志, 2021, 16(03): 310-313.
[7]	王拥军. 新年礼物[J]. 中国卒中杂志, 2019, 14(02): 93-96.
[8]	彭晓霞;秦海强. 基于概念框架的标书撰写方法[J]. , 2009, 4(02): 171-175.